Skip to main
PTGX
PTGX logo

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 42%
Buy 53%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics Inc's increased enterprise value-to-sales (EV/Sales) multiple, rising from 8.0x to 9.5x, reflects strong anticipated growth driven by a favorable mix of milestone payments and royalties expected to generate high margins. The company has demonstrated significant efficacy in its pipeline, particularly with icotrokinra, which shows increased peak market penetration projections and potential revenue of $3.2 billion in psoriasis and $3 billion in ulcerative colitis. Furthermore, the prospect of additional revenue drivers from preclinical assets further enhances Protagonist's growth outlook, supporting a robust future market position.

Bears say

Protagonist Therapeutics Inc faces significant regulatory risks that may lead to delays or rejections in the approval processes of its pipeline products, thereby reducing potential future cash flows and negatively impacting share price. Additionally, the company is expected to continue incurring net losses until its products receive approval and enter the market, with anticipated capital raises posing a dilutive effect on shareholder value. The uncertainties surrounding product uptake, patient recruitment for trials, and negative policy developments further contribute to a negative outlook on the company’s financial health.

Protagonist Therapeutics (PTGX) has been analyzed by 19 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 53% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Buy based on their latest research and market trends.

According to 19 analysts, Protagonist Therapeutics (PTGX) has a Buy consensus rating as of Sep 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.84, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.84, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.